Plasma, myocardial, and skeletal muscle digoxin concentrations were measured in 32 patients undergoing cardiopulmonary bypass who were on long-term treatment with digoxin. Thepatients were divided into 4groups according to their daily digoxin dose and the interval between discontinuation of the drug and operation. Before bypass, the mean digoxin concentrations were I.58 nmol/l (I.24 ng/ml) in plasma, 65.2 nmol/kg (50.9 ng/g) in the atria, I2I.4 nmol/kg (94.8 ng/g) in ii papillary muscles, and I6.6 nmol/kg (I3.0 ng/g) in skeletal muscle. Mean atrial digoxin concentrations were significantly lower than mean papillary muscle concentrations in ii patients. Ratios ofplasma to myocardial or skeletal muscle digoxin concentrations were very variable. Generally digoxin concentrations were higher in patients on the larger digoxin dose and with the shorter discontinuation time before surgery. These differences attained significance only with plasma digoxin concentrations. There was a slightfall in plasma digoxin concentration during cardiopulmonary bypass but no significant differences were observed between plasma, atrial, or skeletal muscle digoxin concentrations before and at the end of bypass. No clear relation was seen between plasma or atrial digoxin concentrations and postoperative cardiotoxicity. Stopping digoxin 48 hours before operation appeared to account for pre-or post-bypass plasma digoxin concentrations of less than I.O nmolfl (o.8 ng/ml) in most of the instances encountered, whereas the 3 patients who developedpulsus bigeminus postoperatively had received o.5 mg digoxin only 24 hours before operation.
The recent introduction of methods enabling the estimation of plasma digoxin concentrations has contributed significantly to knowledge of the clinical pharmacology of this drug. Therapeutic and toxic ranges of plasma digoxin concentrations have been identified in patients on chronic maintenance doses of dixogin (Smith, Butler, and Haber, I969; Smith and Haber, I970; Chamberlain et al., I970;  Evered and Chapman, I97I), though some overlap occurs between the two groups. A surprisingly large proportion of patients admitted to hospital appears to be taking inadequate amounts of digoxin (Carruthers, Kelly, and McDevitt, I974) . Interpretation of plasma digoxin concentrations depends upon the assumption that a relatively constant relation exists between plasma and myocardial receptor site concentrations, since it is the latter (together with the response of the tissue) which ultimately determines the effect of the drug (Smith and Haber, I972) .
The relation between plasma and myocardial tissue digoxin concentrations has been the subject of a number of investigations. Initially Doherty, Received 22 July 1974. Perkins, and Flanigan (I967) suggested that a relatively constant ratio existed between the two, but subsequent investigations have not supported this (Binnion et al., I969; Coltart, Howard, and Chamberlain, I972; Carroll et al., I973) and wide variations in myocardial tissue digoxin concentrations have been reported . Carroll et al. (1973) have recently suggested that there is no difference between the atrial and ventricular concentrations of the drug in humans, but this is at variance with results obtained from dogs (Deutscher, Harrison, and Goldman, I972) and from human necropsy studies after administering radioactive digitoxin (Okita et al., 1955) .
The effects of cardiopulmonary bypass on plasma and tissue digoxin levels have also been in dispute.
A decrease in myocardial digoxin concentration, accompanied by a rise in plasma digoxin levels, has been reported as a result of bypass in both dogs (Austen et al., I962) and humans (Ebert, Morrow, and Austen, I963 Plasma and tissue digoxin concentrations and ratios Plasma, atrial, and skeletal muscle digoxin levels in samples obtained at the onset of bypass are shown in Table 2 . At the onset of bypass the digoxin level in plasma for all subjects ranged from 0.4 tO 3.7 mmol/l (0.3 to 2.9 ng/ml). Five patients had levels greater than 2.6 nmol/l (2.0 ng/ml) and 7 patients had levels less than I nmol/l (o.8 ng/ml). The mean level in all subjects was I.5 nmol/l (I.2 ng/ml). In patients who stopped digoxin, 0.25 mg daily, 48 hours before operation (Group B), plasma digoxin levels (mean I.2 ± 0.4 mmol/l (0.9 ± 0.3 ng/ml)) were significantly lower than in the patients on the same dose whose therapy was stopped 24 hours later (Group A, mean i.8 ± o.6 nmol/l (I.4 ± 0.5 ng/ml)). Patients receiving 0.5 mg daily also had significantly lower plasma digoxin levels when therapy was stopped 48 hours before operation (Group D, mean I.2 + o.6 nmol/l (0.9 ± 0.5 ng/ml)), than those whose digoxin was stopped only 24 hours before surgery (Group C, mean 2.2 ± 0.9 nmol/l (I.7 ± 0.7 ng/ml)).
Atrial digoxin levels ranged from 2.9 tO I66.7 nmol/kg (2.3 tO I30.2 ng/g), with a mean level of 65.2 nmol/kg (50.9 ng/g). The ratio of atrial to plasma digoxin levels ranged from 3.8: I to I24: I with a mean ratio of 46.3: I. Skeletal digoxin levels ranged from 2.6 to 93.I nmol/kg (2.0 to 72.7 ng/g) with a mean level of I6.6 nmol/kg (I3.0 ng/g). Fifty per cent of samples contained between I2.8 and 25.6 nmol/kg (io and 20 ng/g); only 3 patients had skeletal muscle digoxin levels greater than 38.4 nmol/kg (30 ng/g) and only 3 were less than 6.4 nmol/kg (5 ng/g). The mean ratio of skeletal to plasma digoxin concentrations was I3.2:I with a range from I.9: I tO 35.3: I.
For each of the doses, the atrial and skeletal muscle digoxin concentrations were higher 24 hours after stopping therapy than after 48 hours, but these differences were not significant. (Jeliffe, I968) , near normal renal function, and that the studies in rats, using tritiated digoxin which showed that decay occurred in all tissues at the same rate (Okita, 1969) Table 3 . There is a decline in the mean plasma level with an observed miniimum between 30 and go minutes and a return at the end of bypass to levels which approximate to those found initially. None of these changes reaches statistical significance. The overall mean plasma digoxin levels were I.5 nmol/l (1.2 ng/ml) (before bypass), I.4 nmol/l (i.i ng/ml) (io min), I.4 nmol/l (i.i ng/ml) (30 min), I.7 nmol/l (I.3 ng/ml) (go min: n= I4) and I.5 nmol/l (1.2 ng/ml) (end of bypass).
Mean plasma, atrial, and skeletal muscle digoxin levels within each group show no significant change after bypass (Table 2 ). The mean pre-and postbypass tissue levels are distinctly similar: I.5 nmol/l and i.5 nmol/l (I.2 ng/ml and I.2 ng/ml) respectively for plasma, 65.2 nmol/kg (50.9 ng/g) and 64.0 nmol/kg (50.o ng/g), respectively, for atrial muscle and I6.6 nmol/kg and 15.0 nmol/kg (I3.0 ng/g and I I.7 ng/g) for skeletal muscle digoxin concentrations. However, within individual patients there were many occasions when plasma and tissue digoxin levels rose or fell appreciably during the bypass procedure. There was a considerable degree of overlap between these patients and there was no clear evidence of any pattern in the changes observed.
Postoperative clinical course Two patients did not achieve adequate cardiac output on termination of bypass and subsequently died in spite of supportive measures. Postoperative plasma digoxin levels in these patients were within the acceptable range at I.7 and i.8 nmol/l (I.3 and I.4 ng/ml), respectively. Their necropsy studies showed considerable myocardial ischaemia. Two patients, who had low preoperative plasma digoxin levels of 0.5 and o.8 nmol/l (0.4 and o.6 ng/ml), developed rapid atrial fibrillation within 6 to 8 hours of operation, which responded to further digoxin therapy. Three patients whose plasma digoxin levels at the end of bypass were I.8, 2.8, and 4.I nmol/l (I.4, 2.2, and 3.2 ng/ml), subsequently developed runs of pulsus bigeminus. However, 5 patients whose plasma digoxin levels had not been above o.9 nmol/l (0.7 ng/ml) and 2 patients with post-bypass plasma concentrations of 2.7 and 3.7 nmol/l (2.I and 2.9 ng/ml) underwent their operations without any postoperative complications. Three patients died within I4 days of the study as a result of thromboembolic complications. This problem has been described elsewhere (Cleland and Molloy, I973) .
Discussion
The patients in this study had all been in heart failure and the majority suffered also from atrial group.bmj.com on July 6, 2017 -Published by http://heart.bmj.com/ Downloaded from (Binnion et al., I969) or have brought together patients with both different dosage regimens and different intervals between drug discontinuation and operation (Carroll et al., 1973) . In these studies, the results were analysed in total groups. While such variations may not affect plasma/tissue digoxin concentration ratios, they will undoubtedly affect the values obtained for individual plasma and tissue digoxin concentrations as is shown in the present study by the results in Table 2 .
The atrial digoxin levels in this study ranged from 2.9 to I66.7 nmol/kg (2.3 to I30.2 ng/g), with a mean of 65.2 nmol/kg (50.9 ng/g). These results appear lower than those obtained by Carroll et al. (I973), but i6 of their 2i patients were taking digoxin, o.5 mg daily or greater, and it is not clear how many of these discontinued their therapy only 24 hours before operation. Similarly, higher mean atrial digoxin concentrations have been reported by Binnion et al. (i969) The similarity between the mean atrial digoxin concentration 97.9 nmol/kg (76.5 ng/g) obtained by Carroll et al. (I973) and the mean left ventricular papillary muscle concentration reported by Coltart et al. (1972) led Carroll and his colleagues to postulate that there is no difference between atrial and ventricular concentration of the drug in patients on digoxin therapy. However, in our ii patients, the mean digoxin level in papillary muscle was significantly greater than that in atrial muscle. This finding is in accord with atrioventricular digoxin concentration relations previously demonstrated in animals (Gruber, Luchi, and Turnbull, i967; Deutscher et al., 1972) , in human necropsy material (Okita et al., I955) and in the patients in this present study who came to necropsy (S. G. Carruthers, J. G. Kelly and D. G. McDevitt, unpublished observations). Why different parts of the myocardium should have distinctly different digoxin concentrations remains uncertain.
Skeletal muscle digoxin concentrations also show a gradient for different dosage levels and time intervals (Table 2) . In this case, with the small numbers of patients within the groups, the differences did not attain significance. Extrapolation to zero-time gave mean skeletal muscle digo-xin con-centrations of 28.3 nmol/kg (22.I ng/g) for patients taking 0.25 mg and 34.4 nmol/kg (26.9 ng/g) for a daily dose of 0.5 mg. Therefore, the possibility exists for differentials between mean skeletal muscle digoxin concentrations attained at different daily digoxin dosages. The ratio of atrial to skeletal muscle digoxin concentrations (about 4: I) is in agreement with that described in dogs given tritiated digoxin intravenously (Deutscher et al., I972) .
In this present study the ratios of plasma digoxin concentrations to the concentrations found in other tissues showed a similar variability to that described by previous authors (Doherty et Reasons for the observed variability in ratios between plasma and myocardial digoxin have been reviewed by Coltart et al. (I972) . They suggest that plasma digoxin concentrations may provide a more maningful index of therapeutic activity than total myocardial concentrations as only about I0 per cent of myocardial digoxin may be bound to active sites (Kuschinsky et al., I967) .
The effect of cardiopulmonary bypass on plasma digoxin concentrations was similar to that shown by Coltart et al. (I97I) . The plasma digoxin levels did not fall as low or remain low for as long as in Coltart's study, but the mean initial plasma digoxin concentration was lower and the mean duration of bypass shorter. A decline in plasma digoxin level was seen as soon as I0 minutes after the institution of bypass and this supports the idea that it probably represents a dilution of the plasma volume by pump and intravenous infusion fluids.
In addition, our findings indicate that there is no appreciable loss of digoxin from the atrial tissue during cardiopulmonary bypass in patients on chronic maintenance digoxin therapy. This is in agreement with the recent study in 8 dogs by Molokhia et al. (197I) and the clinical observations of Beall et al. (1963) . Previously, loss of myocardial digoxin during cardiopulmonary bypass had been reported both in animals (Austen et al., I962) and in man (Ebert et al., I963) . It now appears, however, that evidence is accumulating for maintenance of digoxin concentration in myocardial tissue during bypass.
In the four groups of patients under study, the skeletal muscle digoxin concentrations fell on average by o.6 to 3.2 nmol/kg (o.s tO 2.5 ng/g) with an Coltart et al. (1972) showed that a mean total of 0.2 mmol (0.I34 mg) digoxin was lost from the urinary tract and a much smaller amount via the oxygenator and discard suction bottle during bypass over an average of 8 hours in i i patients on maintenance digoxin therapy. They felt that this amount was comparable to the normal urinary digoxin excretion in these people under normal circumstances, but if there were an actual loss of digoxin during bypass, this present study would suggest that restoration of plasma and myocardial digoxin levels could occur with only trivial changes in skeletal muscle digoxin concentrations. Despite the wide variations between subjects in the levels of digoxin found in the various tissues, there must be a fairly stable relation within each individual as a mere i per cent shift of digoxin from skeletal muscle to plasma would produce a ioo per cent increase in plasma digoxin concentration, and a 5 per cent transfer from skeletal muscle to the myocardium would double the cardiac level. Such changes in plasma and cardiac digoxin concentration could be of great importance, yet the changes in skeletal muscle digoxin would be difficult to measure.
The patient undergoing cardiopulmonary bypass appears to be at particular risk if his digoxin dosage is inadequate or excessive. Lack of digitalis predisposes to poor inotropic action at a time when the myocardium has suffered the mechanical injury of surgery, and the poor pump performance may be aggravated by inadequately controlled atrial fibrillation. Metabolic changes may increase myocardial irritability (Pacifico, Digerness, and Kirklin, I970) thereby accentuating the dangerous arrhythmias of digoxin toxicity. Plasma digoxin concentrations from I.0-2.6 nmol/l (0.8-2.0 ng/ml) have been described as being within 'the observed "normal" therapeutic range' (Whiting, Sumner, and Goldberg, I973) for patients with normal renal function on standard daily digoxin dosage. In addition, plasma digoxin levels of 2.6 nmol/l (2.0 ng/ml) or greater demand caution as they are often associated with impending or actual digoxin toxicity.
In the present study, approximately two-thirds of the patients had satisfactory pre-bypass plasma digoxin levels -consistent with their normal or near normal renal function and relatively young average age group. Five patients had levels greater than 2.6 nmol/l (2.0 ng/ml) before bypass and of these two developed cardiac arrhythmias after surgery; 2 patients developed rapid atrial fibrillation within 6 to 8 hours of operation which responded to further digoxin and both of these came from the group of 7 patients who had pre-bypass plasma digoxin concentrations less than I.O nmol/l (o.8 ng/ml). 85.4, II2.0, and 94 nmol/kg (66.7, 87.5, and 73.7 ng/g), respectively, but no arrhythmia occurred in IO other patients with post-bypass atrial concentrations ranging from 76.8 to I70.3 nmol/kg (6o to I33 ng/g). Hence knowledge of atrial digoxin concentration does not appear to be of value in the prediction of postbypass arrhythmias.
The 5 patients whose postoperative complications might definitely be associated with inadequate (2) or excessive digoxin administration (3) had all been on 0.5 mg digoxin daily. The 2 patients who developed fast atrial fibrillation had stopped treatment 48 hours before operation, while the 3 patients who developed pulsus bigeminus had received their last o.5 mg dose only 24 hours before operation. The group of patients on 0.25 mg daily who stopped treatment for 48 hours before operation included 5 (out of a total of 8) whose post-bypass plasma levels were less than I.O nmol/l (o.8 ng/ml), though no evidence of inadequate digoxin treatment developed. 
